Before and after molnupiravir/ritonavir (Paxlovid(R)), there have been monoclonal antibodies and other antivirals. However, molnupiravir/ritonavir can be taken orally and might have a high effectiveness in preventing severe COVID-19 for those at an increased risk for it. We discuss the recently published EPIC-HR study as well as the broader implications.

0:00 Intro

2:01 Pax Romana

2:44 Outpatient Options for Early Treatment to Prevent Hospitalization

6:03 PF-0731332 (nirmatrelvir)

8:33 Paxlovid (Nirmatrelvir-Ritonavir)

10:12 Research on Nirmatrelvir

11:18 The EPIC-HR Study

13:37 Author Affiliations

14:03 Inclusion and exclusion criteria

15:36 Results with subgroup analysis

19:27 Should we believe Paxlovid results?

21:15 Can Paxlovid be used in our patients?

22:35 Absolute contra-indications

23:25 Relative contra-indications

24:52 Should we use Paxlovid over others?

28:01 Can we use Paxlovid for ourselves?

29:11 Summary: Paxlovid Utility

31:00 What's next for Paxlovid?

32:38 Paxlovid Romana?

33:54 Q&A

Speaker: Warren Chuang, MD, MA; Massachusetts General Hospital/Harvard Medical School

Recording date: May 19,2022

Ref: Hammond J et al. N Engl J Med 2022; 386:1397-1408 doi: 10.1056/NEJMoa2118542

#paxlovid #covid19 #treatment

Hosted on Acast. See acast.com/privacy for more information.